277 related articles for article (PubMed ID: 10190945)
1. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
Stelitano C; Morabito F; Kropp MG; Callea V; Iuliano F; Oriana V; Levato D; Nobile F; Molica S; Brugiatelli M
Haematologica; 1999 Apr; 84(4):317-23. PubMed ID: 10190945
[TBL] [Abstract][Full Text] [Related]
2. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G
Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
[TBL] [Abstract][Full Text] [Related]
3. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy.
Marotta G; Bigazzi C; Lenoci M; Tozzi M; Bocchia M; Lauria F
Haematologica; 2000 Dec; 85(12):1268-70. PubMed ID: 11114133
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
Bergmann MA; Goebeler ME; Herold M; Emmerich B; Wilhelm M; Ruelfs C; Boening L; Hallek MJ;
Haematologica; 2005 Oct; 90(10):1357-64. PubMed ID: 16219572
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
[TBL] [Abstract][Full Text] [Related]
9. High dose chlorambucil versus Binet's modified cyclophosphamide, doxorubicin, vincristine, and prednisone regimen in the treatment of patients with advanced B-cell chronic lymphocytic leukemia. Results of an international multicenter randomized trial. International Society for Chemo-Immunotherapy, Vienna.
Jaksic B; Brugiatelli M; Krc I; Losonczi H; Holowiecki J; Planinc-Peraica A; Kusec R; Morabito F; Iacopino P; Lutz D
Cancer; 1997 Jun; 79(11):2107-14. PubMed ID: 9179056
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
[TBL] [Abstract][Full Text] [Related]
11. Severe autoimmune hemolytic anemia in eight patients treated with fludarabine.
Gonzalez H; Leblond V; Azar N; Sutton L; Gabarre J; Binet JL; Vernant JP; Dighiero G
Hematol Cell Ther; 1998 Jun; 40(3):113-8. PubMed ID: 9698219
[TBL] [Abstract][Full Text] [Related]
12. In vitro sensitivity of chronic lymphocytic leukemia B-cells to fludarabine, 2-chlorodeoxyadenosine and chlorambucil: correlation with clinico-hematological and immunophenotypic features.
Morabito F; Stelitano C; Callea I; Filangeri M; Oliva B; Sculli G; Callea V; Nobile F; Brugiatelli M
Haematologica; 1996; 81(3):224-31. PubMed ID: 8767527
[TBL] [Abstract][Full Text] [Related]
13. Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity.
Spriano M; Clavio M; Carrara P; Canepa L; Miglino M; Pierri I; Celesti L; Rossi E; Vimercati R; Bruni R
Haematologica; 1994; 79(3):218-24. PubMed ID: 7926970
[TBL] [Abstract][Full Text] [Related]
14. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
Martell RE; Peterson BL; Cohen HJ; Petros WP; Rai KR; Morrison VA; Elias L; Shepherd L; Hines J; Larson RA; Schiffer CA; Hurwitz HI
Cancer Chemother Pharmacol; 2002 Jul; 50(1):37-45. PubMed ID: 12111110
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up after fludarabine treatment in pretreated patients with chronic lymphocytic leukemia.
Zinzani PL; Bendandi M; Magagnoli M; Albertini P; Rondelli D; Stefoni V; Tani M; Tura S
Haematologica; 2000 Nov; 85(11):1135-9. PubMed ID: 11064464
[TBL] [Abstract][Full Text] [Related]
16. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone.
Mauro FR; Gentile M; Mancini F; Giannarelli D; Guarini A; De Propriis MS; Cerretti R; Foa R
Haematologica; 2002 Jun; 87(6):602-8. PubMed ID: 12031916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
